<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Whole exome/genome sequencing has been fundamental in the identification of <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in the spliceosome machinery in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) and other <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>SF3B1, splicing factor 3b subunit 1 is mutated in 60%-80% of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> associated with <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T), 2 distinct subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MDSs/MPNs) </plain></SENT>
<SENT sid="2" pm="."><plain>An idiosyncratic feature of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T is the presence of abnormal sideroblasts characterized by <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in the mitochondria, called RS </plain></SENT>
<SENT sid="3" pm="."><plain>Based on the high frequency of mutations of SF3B1 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T, we investigated the consequences of SF3B1 alterations </plain></SENT>
<SENT sid="4" pm="."><plain>Ultrastructurally, SF3B1 mutants showed altered iron distribution characterized by coarse iron deposits compared with <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> patients by transmission electron microscopy </plain></SENT>
<SENT sid="5" pm="."><plain>SF3B1 knockdown experiments in K562 cells resulted in down-regulation of U2-type intron-splicing by RT-PCR </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="40" ids="33697">RNA</z:chebi>-sequencing analysis of SF3B1 mutants showed differentially used genes relevant in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> pathogenesis, such as ASXL1, CBL, EZH, and RUNX families </plain></SENT>
<SENT sid="7" pm="."><plain>A SF3B pharmacologic inhibitor, meayamycin, induced the formation of RS in healthy BM cells </plain></SENT>
<SENT sid="8" pm="."><plain>Further, BM aspirates of Sf3b1 heterozygous knockout mice showed RS by <z:chebi fb="27" ids="30069">Prussian blue</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, we report the first experimental evidence of the association between SF3B1 and RS phenotype </plain></SENT>
<SENT sid="10" pm="."><plain>Our data suggest that SF3B1 haploinsufficiency leads to RS formation </plain></SENT>
</text></document>